CXCL12 inhibitor

DRUG CLASS:

CXCL12 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	NOX-A12 Sensitive: B - Late Trials NOX-A12 Sensitive : B	NOX-A12 Sensitive: B - Late Trials NOX-A12 Sensitive : B
HRAS mutation	Urothelial Cancer	HRAS mutation	Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3
HRAS G13R	Urothelial Cancer	HRAS G13R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS Q61R	Urothelial Cancer	HRAS Q61R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12S	Urothelial Cancer	HRAS G12S	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12C	Urothelial Cancer	HRAS G12C	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS H27_28fs*	Urothelial Cancer	HRAS H27_28fs*	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS mutation	Salivary Gland Cancer	HRAS mutation	Salivary Gland Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
CXCL12 expression	Peripheral T-cell Lymphoma	CXCL12 expression	Peripheral T-cell Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
HRAS overexpression	Squamous Cell Carcinoma of Head and Neck	HRAS overexpression	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
HRAS overexpression + PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	HRAS overexpression + PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
CXCL12 expression	Glioblastoma	CXCL12 expression	Glioblastoma	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3
HRAS overexpression + PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	HRAS overexpression + PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
RAD51AP1 overexpression	Hepatocellular Cancer	RAD51AP1 overexpression	Hepatocellular Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
RET exon 11 deletion	Thyroid Gland Medullary Carcinoma	RET exon 11 deletion	Thyroid Gland Medullary Carcinoma	sorafenib + tipifarnib Sensitive: C4 – Case Studies sorafenib + tipifarnib Sensitive : C4	sorafenib + tipifarnib Sensitive: C4 – Case Studies sorafenib + tipifarnib Sensitive : C4
HRAS mutation	Rhabdomyosarcoma	HRAS mutation	Rhabdomyosarcoma	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS G12C	Squamous Cell Carcinoma of Head and Neck	HRAS G12C	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS A146T	Squamous Cell Carcinoma of Head and Neck	HRAS A146T	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS K117N	Squamous Cell Carcinoma of Head and Neck	HRAS K117N	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS G13R	Squamous Cell Carcinoma of Head and Neck	HRAS G13R	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS G12S	Squamous Cell Carcinoma of Head and Neck	HRAS G12S	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
PIK3CA mutation + HRAS mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation + HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D

CXCL12 inhibitor

CXCL12 inhibitor

Associations(39)

Associations
(39)